Monitor for UPSTREAM MG topline data in 1H27 and potential regulatory filings for telitacicept in US/EU/Japan. Cash runway into early 2029 reduces near-term dilution risk, but the stock remains binary on clinical outcomes.
Drug in focus
VOR drug pipeline →telitacicept
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3 (global); Approved in China (SLE, IgAN, SjD)
- Time to market
- Telitacicept is already marketed in China for SLE. For US/EU approval, the earliest potential timeline depends on the global Phase 3 UPSTREAM MG readout (1H 2027) followed by BLA submissions, with potential approval possibly in 2028-2029 if results are positive.
- Next catalyst
- None dated
What to watchThe next major catalyst is the topline readout from the global Phase 3 UPSTREAM MG trial in generalized myasthenia gravis, expected in the first half of 2027. Positive data would support US/EU regulatory filings and validate Vor Bio's strategy of replicating RemeGen's Chinese clinical success globally. Negative or mixed results would severely damage the thesis, as telitacicept is Vor Bio's lead asset. Also watch for enrollment completion updates from the UPSTREAM SjD Phase 3 trial in Sjogren's disease.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $23.37entry
- T+1 · 3mo ago −4.41%α −4.66% · $22.34
- T+5 · 3mo ago −0.39%α +0.02% · $23.28
- T+20 · 2mo ago −0.58%α +0.48% · $23.24
- T+60 · 13d ago −14.98%α −14.84% · $19.87
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vor Bio reported Q2 2026 financial results with net loss of $62.8M, cash of $466.1M (plus $48.4M from July ATM sales), and provided pipeline updates for telitacicept. Phase 3 UPSTREAM MG and UPSTREAM SjD trials are enrolling with topline data expected in 1H27. As a pre-revenue clinical-stage biotech, the filing is a routine quarterly update with no material financial surprises.
Key Facts
- Cash, cash equivalents and marketable securities were $466.1M as of June 30, 2026, with $48.4M additional net proceeds from ATM sales in July 2026, providing runway into early 2029.
- Net loss for Q2 2026 was $62.8M, compared to $1,573.7M in Q2 2025 (decrease primarily due to change in fair value of liability-classified warrants).
- R&D expenses were $25.9M vs $261.5M in Q2 2025; G&A expenses were $21.9M vs $12.8M.
- Enrollment ongoing in global Phase 3 UPSTREAM MG trial for generalized myasthenia gravis and UPSTREAM SjD trial for primary Sjögren's disease, with topline data from UPSTREAM MG anticipated in 1H27.
- Telitacicept received commercial approvals in China for Sjögren's disease and IgA nephropathy; Phase 3 TELIGAN results published in NEJM.
- Appointed David Zaccardelli to Board of Directors.
Financial Impact
Net loss of $62.8M; cash position of $466.1M plus $48.4M ATM proceeds; no revenue reported.
Risk Factors
- Clinical trial failure or delay in UPSTREAM MG or UPSTREAM SjD
- Regulatory setbacks in US/EU/Japan despite China approvals
- Competition from other BAFF/APRIL inhibitors in autoimmune indications
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342846 |
Track record
17 reports on VOR
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +70.35% at T+60 after the Jun 8, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.97 Now $18.97 −0.00% settles Nov 18
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.32 to $19.42 Now $18.97 −1.81% ▲ +0.52% +0.88% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $18.66 to $19.88 Now $18.97 +1.66% ▲ +6.54% +6.23% vs SPY
- Oct 30, 202617d ago 424B5 Bearish 4/10 Entry $19.68 to $19.25 Now $18.97 +3.61% ▲ +2.19% +1.71% vs SPY
- Oct 30, 202617d ago Press Release Neutral 4/10 Entry $19.68 to $19.25 Now $18.97 −3.61% ▼ −2.19% −1.71% vs SPY
- Oct 22, 202625d ago Press Release Bullish 7/10 Entry $18.26 to $18.33 Now $18.97 +3.89% ▲ +0.38% −0.33% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $18.31 to $18.78 Now $18.97 +3.60% ▲ +2.57% +2.81% vs SPY
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $18.33 to $19.08 Now $18.97 +3.49% ▲ +4.09% +4.30% vs SPY
- Aug 11, 202613w ago Press Release Neutral 3/10 Viewing Entry $23.37 to $22.34 Now $18.97 −18.83% ▼ −4.41% −4.66% vs SPY
- Jul 9, 202618w ago 3 Neutral 2/10 Entry $19.14 to $18.03 Now $18.97 −0.89% ▼ −5.80% −5.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers